Revolutionary Treatment Brings Sight Back to Young Stevenage Girl
At just six years old, Saffie Sandford has regained her sight through an extraordinary gene therapy available on the NHS. This pioneering treatment directly injected a healthy copy of the gene into her eye, reversing the effects of her rare inherited eye condition.
Conquering Leber’s Congenital Amaurosis with Cutting-Edge Medicine
Saffie, a resident of Stevenage, Hertfordshire, suffers from Leber’s Congenital Amaurosis (LCA), a genetic disorder that prevents the eye’s cells from producing a vital protein required for normal vision. This condition severely limits vision in daylight and causes complete blindness in low light, typically leading to total sight loss in adulthood.
Without intervention, doctors warned Saffie would lose her sight by age 30.
Diagnosis and Treatment Journey
A devoted Spider-Man fan, Saffie was diagnosed at Moorfields Eye Hospital in London after her parents noticed difficulties seeing in the dark. She then received the revolutionary gene therapy, Luxturna, at Great Ormond Street Hospital (GOSH).
Luxturna, a one-time injection, delivers a functional gene to restore the eye’s ability to produce the missing protein, marking a first-of-its-kind treatment for this genetic cause of LCA.
A Mother’s Emotional Perspective
Saffie’s mother, Lisa Sandford, reflected on the family’s ordeal: “Saffie’s diagnosis was a huge shock. We had never heard of LCA, nor knew that Tam and I were carriers.”
Lisa described the condition as “life-limiting,” especially because Saffie was blind in darkness, making everyday activities a struggle.
“The gene therapy has been life-changing,” Lisa said. “It’s like magic—her sight in the dark was restored overnight.”
She shared how the treatment allowed the family to enjoy activities previously impossible, such as trick-or-treating and dining out in the evening.
Transformative Results and Bright Future
Saffie underwent gene therapy in April for her first eye, followed by treatment in her second eye in September. Already diagnosed with short-sightedness at age two, she wore glasses before the therapy.
Her peripheral vision in daylight has also improved dramatically, enabling her to detect hazards more easily and excel in school.
Lisa proudly noted, “Saffie is thriving. You wouldn’t even know she has this condition now. She enjoys normal six-year-old activities like playing on climbing frames.”
“The results have been incredible. We are eternally grateful that our little girl has been given her sight back,” Lisa added. “While we understand it might not last forever, we cherish every day she has this chance.”
Scientific Breakthrough Backed by Research
Recent studies from Great Ormond Street Hospital and University College London (UCL) confirm that Luxturna not only improves vision but also strengthens visual pathways during critical stages of brain development, underscoring the therapy’s profound impact.
